Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

October 15, 2014 09:00 ET

Critical Outcome Adds a Canadian Patent to COTI-2's Growing Intellectual Property Portfolio

P53-Dependent Cancer Treatment IP Coverage Extended to Home Market

LONDON, ONTARIO--(Marketwired - Oct. 15, 2014) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT)(OTCQB:COTQF), the bioinformatics and accelerated drug discovery company, announced today that its lead cancer drug candidate, COTI-2, has received its first Canadian patent, adding to a portfolio that includes six U.S. patents and one Japanese patent.

"This Canadian composition of matter patent follows on the heels of our recently announced sixth U.S. and first Japanese patent, further solidifying the intellectual property position surrounding our lead oncology asset," said Dr. Wayne Danter, President and CEO. "As we continue the development of COTI-2 towards a clinical trial, we are building a strong patent portfolio that will support and facilitate future commercial licensing opportunities."

Canadian Patent No. 2,673,683 covers the COTI-2 family of compounds, pharmaceutical preparations containing COTI-2, and methods of manufacturing the compounds. This subject matter has previously been covered in patents received in the U.S. and Japan.

About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit

Follow @CriticalOutcome on Twitter at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information